Factor VIII, recombinant

From HemOnc.org - A Hematology Oncology Wiki
Revision as of 01:04, 29 June 2024 by Warner-admin (talk | contribs) (Text replacement - "please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [https://online.lexi.com/lco/action/login UpToDate Lexidrug], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information" to "please refer to your preferred pharmacopeias or the prescribing information")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

General information

Class/mechanism: Recombinant Factor VIII; replaces the missing clotting factor VIII that is required for hemostasis in patients with hemophilia A.
Please choose from the products below to find specific drug/manufacturer information:

Route: IV
Extravasation: no information

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.

Diseases for which it is used

  • Hemophilia A

Patient drug information

Also known as

  • Generic name: recombinant coagulation factor 8
  • Brand names: Advate rAHF-PFM, Helixate, Helixate FS, Kogenate, Kogenate FS, Recombinate, Refacto, Xyntha

References